Chemomab Halves Combined-Company Share Count to 5M in Merger Amendment No. 2
CMMB is trading near its 52-week low of $1.051 (13% above the low) on light trading volume (0.4× avg).
Summary
Chemomab's Amendment No. 2 to the Domestication Merger cuts the Combined Company's post-closing share count from 10 million to 5 million while leaving the Chemomab/Scipher ownership split unchanged, and revises the CVR agreement to add quarterly status reports and remove registration-related payment tolling.
Key Events · M&A and Partnerships · CMMB
-
Combined-Company Share Count Halved
Amendment No. 2 reduces the post-closing Combined Company share count from 10,000,000 to 5,000,000, halving the Chemomab Allocation used in the Domestication Exchange Ratio.
-
Ownership Split Unchanged
Chemomab states the amendment is technical and does not change consideration, economic value, or the relative ownership allocation between Chemomab and Scipher.
-
CVR Milestones Quantified
CVR holders receive $40,000,000 on Phase III initiation in PSC or a Disposition of the Product, and $10,000,000 on FDA approval, over a seven-year term with a $600,000 expense cap.
-
CVR Reporting and Payment Mechanics Revised
Parent must deliver quarterly Status Reports within 45 days of quarter end, and the tolling of payment periods pending registration effectiveness, plus the cash-only fallback, were removed.
Analysis · CMMB · Life Sciences
The post-closing share count of the Combined Company drops from 10 million to 5 million under Amendment No. 2, halving the Chemomab Allocation that feeds the Domestication Exchange Ratio. Chemomab describes the change as technical, leaving consideration, economic value, and the relative ownership split between Chemomab and Scipher untouched; the 32% Chemomab / 68% Scipher allocation previously disclosed in the S-4 therefore stands. The genuinely new element is the CVR package: holders receive $40 million on Phase III initiation in PSC (or a Disposition of the Product) and $10 million on FDA approval, over a seven-year term, with a $600,000 expense cap, quarterly status reports, and removal of the tolling/cash-only fallback tied to registration effectiveness. Against a going-concern warning and roughly $6.7 million of cash as of June 30, 2026, the CVRs represent the only meaningful upside beyond the merger itself, and the halved share count changes the per-share math of the Combined Company without changing who owns what.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMMB was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2M. The 52-week trading range was $1.05 to $3.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.